Neurogen Corporation: Premium Company Profile

Questions: Discounts, Updates etc.

Price: $495.00

Publication Date: 2008-01-01

Order Online Now

People that purchased this report also purchased:

Contact LeadDiscovery

  • If you have questions about this report
  • To find out if you qualify for a discount
  • Want a more up to date version
  • Can't find a report that meets your needs
Search all reports

Keywords:

Boolean terms AND, OR, NOT can be used. Phrases should be entered within quotes. For wildcards use an *

Neurogen is a drug discovery and development company founded in 1987. The company established its presence in the pharmaceutical market by partnering with Pfizer and American Home Products in 1999. In addition, the company's proprietary technology, Accelerated Intelligent Drug Discovery (AIDD), is the result of a successful collaboration with Merck for VR-1 research programs.


Scope

  • Contains corporate strategy, value chain presence and SWOT Analysis
  • Provides detailed business description, segment analysis, 5-year financial trends, key products and key competitors
  • Includes information on suppliers/ partners, shareholding structure and key employees with biographies


    • Report Highlights
    Neurogen is focused on developing small molecule drugs for disorders with unmet medical need, including insomnia, pain, obesity, depression and inflammation. The company utilizes its proprietary technology, Accelerated Intelligent Drug Discovery (AIDD), for discovering and optimizing potential drug leads.

    The key elements of the company's business strategy include: advancing clinical development of its product candidates, acquiring potential product candidates through licensing agreements and continue to maximize the success of VR-1 research program with Merck.

    The company's total revenues declined at a CAGR of 11.1% during 2002-2006, from $15.7 million to $9.8 million. This represents an absolute total decline of -$5.9 million for total revenues. The decline is primarily due to the termination of the company's research collaboration with Aventis in September 2004.


    Reasons to Purchase

  • Access all the important information and analysis on the company in a single report
  • Understand company's strengths, weaknesses, opportunities and threats along with business strategy and value chain
  • Gain access to company's adjusted five year financial data along with key ratios and market capitalization

    • Table of Contents

    Other users found this report page using the following search terms: neurogen manly corporation pipeline charles aplindore krause adipiplon e pharmaceuticals

    If you can't find a report that meets your needs contact LeadDiscovery. We are one of the few report providers with extensive drug development experience and we frequently use this knowledge to help clients source the most appropriate reports or produce reports for them from scratch.


    Refund and Cancellation Policy: The descriptions of the products and services sold on LeadDiscovery.co.uk are as complete and accurate as possible, and customers are encouraged to read all available information about a product before placing an order. Due to the nature of the information being sold, orders for reports cannot be canceled.